Beam Therapeutics (BEAM) said Thursday the US Food and Drug Administration cleared its investigational new drug application for BEAM-302 to treat alpha-1 antitrypsin deficiency, an genetic disorder that affects lungs or liver.
Earlier this month, Beam disclosed initial safety and efficacy data from a global phase 1/2 study, showcasing the "first ever" clinical genetic correction of a disease-causing mutation, Giuseppe Ciaramella, president of Beam, said late Thursday.
The company plans to continue the dose-escalation portion of part A of the trial, including enrolling and dosing a fourth cohort. It expects to report further data during H2. In addition, it plans to dose the first patient in Part B, including AATD patients with mild-to-moderate liver disease in H2.
In addition to the US, the investigational formulation has received clinical trial authorization in the UK, New Zealand, Australia, the Netherlands, and Ireland.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。